286 related articles for article (PubMed ID: 19349600)
1. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.
Nghiemphu PL; Liu W; Lee Y; Than T; Graham C; Lai A; Green RM; Pope WB; Liau LM; Mischel PS; Nelson SF; Elashoff R; Cloughesy TF
Neurology; 2009 Apr; 72(14):1217-22. PubMed ID: 19349600
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
Galanis E; Anderson SK; Lafky JM; Uhm JH; Giannini C; Kumar SK; Kimlinger TK; Northfelt DW; Flynn PJ; Jaeckle KA; Kaufmann TJ; Buckner JC
Clin Cancer Res; 2013 Sep; 19(17):4816-23. PubMed ID: 23833308
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
4. Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.
Tabouret E; Barrie M; Thiebaut A; Matta M; Boucard C; Autran D; Loundou A; Chinot O
J Neurooncol; 2013 Sep; 114(2):191-8. PubMed ID: 23756726
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
Vredenburgh JJ; Cloughesy T; Samant M; Prados M; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Das A; Friedman HS
Oncologist; 2010; 15(12):1329-34. PubMed ID: 21147867
[TBL] [Abstract][Full Text] [Related]
6. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF
AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647
[TBL] [Abstract][Full Text] [Related]
9. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.
Prados M; Cloughesy T; Samant M; Fang L; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Vredenburgh J; Das A; Friedman HS
Neuro Oncol; 2011 Jan; 13(1):143-51. PubMed ID: 21084434
[TBL] [Abstract][Full Text] [Related]
10. Impact of bevacizumab chemotherapy on craniotomy wound healing.
Clark AJ; Butowski NA; Chang SM; Prados MD; Clarke J; Polley MY; Sughrue ME; McDermott MW; Parsa AT; Berger MS; Aghi MK
J Neurosurg; 2011 Jun; 114(6):1609-16. PubMed ID: 21142749
[TBL] [Abstract][Full Text] [Related]
11. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
Wefel JS; Cloughesy T; Zazzali JL; Zheng M; Prados M; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Vredenburgh J; Das A; Friedman HS
Neuro Oncol; 2011 Jun; 13(6):660-8. PubMed ID: 21558074
[TBL] [Abstract][Full Text] [Related]
12. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.
Iwamoto FM; Abrey LE; Beal K; Gutin PH; Rosenblum MK; Reuter VE; DeAngelis LM; Lassman AB
Neurology; 2009 Oct; 73(15):1200-6. PubMed ID: 19822869
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Nayak L; Molinaro AM; Peters K; Clarke JL; Jordan JT; de Groot J; Nghiemphu L; Kaley T; Colman H; McCluskey C; Gaffey S; Smith TR; Cote DJ; Severgnini M; Yearley JH; Zhao Q; Blumenschein WM; Duda DG; Muzikansky A; Jain RK; Wen PY; Reardon DA
Clin Cancer Res; 2021 Feb; 27(4):1048-1057. PubMed ID: 33199490
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Buie LW; Valgus J
Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).
Soffietti R; Trevisan E; Bertero L; Cassoni P; Morra I; Fabrini MG; Pasqualetti F; Lolli I; Castiglione A; Ciccone G; Rudà R
J Neurooncol; 2014 Feb; 116(3):533-41. PubMed ID: 24293233
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Schaub C; Tichy J; Schäfer N; Franz K; Mack F; Mittelbronn M; Kebir S; Thiepold AL; Waha A; Filmann N; Banat M; Fimmers R; Steinbach JP; Herrlinger U; Rieger J; Glas M; Bähr O
J Neurooncol; 2016 Aug; 129(1):93-100. PubMed ID: 27193554
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
Kreisl TN; Kim L; Moore K; Duic P; Royce C; Stroud I; Garren N; Mackey M; Butman JA; Camphausen K; Park J; Albert PS; Fine HA
J Clin Oncol; 2009 Feb; 27(5):740-5. PubMed ID: 19114704
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
Gutin PH; Iwamoto FM; Beal K; Mohile NA; Karimi S; Hou BL; Lymberis S; Yamada Y; Chang J; Abrey LE
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):156-63. PubMed ID: 19167838
[TBL] [Abstract][Full Text] [Related]
20. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.
Hamza MA; Mandel JJ; Conrad CA; Gilbert MR; Yung WK; Puduvalli VK; DeGroot JF
J Neurooncol; 2014 Aug; 119(1):135-40. PubMed ID: 24803001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
